Nathaniel H. Boyd

Nathaniel H. Boyd

Auto-generated profile, based on publicly available information

Nathaniel H. Boyd

Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294 USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2017 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
ATAnh Tran
Anh Tran
NBNathaniel H. Boyd
Nathaniel H. Boyd
Kiera WalkerKiera Walker
Kiera Walker
AHAnita Hjelmeland
Anita Hjelmeland
Significance: Gliomas are central nervous system tumors that primarily occur in the brain and arise from glial cells. Gliomas include the most common malignant brain tumor in adults known as grade IV astrocytoma, or glioblastoma. Glioblastoma is a deadly disease for which the most significant advances in treatment offer an improvement in survival of only approximately two months. Critical Issues: To develop novel treatments and improve patient outcomes, we and others have sought to determine the role of molecular signals in gliomas. Recent Advances: One signaling molecule that mediates important biologies in glioma is the free radical nitric oxide. In glioma cells and the tumor microenvironment, nitric oxide (NO) is produced by three isoforms of nitric oxide synthase (NOS), NOS1, NOS2, and NOS3. NO and NOS effect glioma growth, invasion, angiogenesis, immunosuppression, differentiation state, and therapeutic resistance. Future directions: These multi-faceted effects of NO and NOS on gliomas both in vitro and in vivo suggest the potential of modulating the pathway for anti-glioma patient therapies.

14 June 2018 in Biomarker Research
Verified
Journal Article
Open access
PDF file
Kiera WalkerKiera Walker
Kiera Walker
NBNathaniel H. Boyd
Nathaniel H. Boyd
JAJoshua C Anderson
Joshua C Anderson
CWChristopher Douglas Willey
Christopher Douglas Willey
AHAnita Hjelmeland
Anita Hjelmeland
For glioblastoma (GBM) treatments to be effective in vivo, understanding the effects of the tumor microenvironment is imperative. In traditional cell culture conditions, glucose concentrations do not model physiologic levels, nor the diminished concentrations found in tumor niches. We therefore sought to profile the differences in kinase activity in GBM cells cultured in restricted glucose to identify pathways that could be targeted with small molecule inhibitors. Using the PamStation12 platform, we examined the ability of GBM lysates from cells cultured in standard or low glucose conditions to phosphorylate 144 tyrosine and 144 serine/threonine peptides that correspond to known protein phosphorylation sites. Potential kinase targets were identified and validated using small molecule kinase inhibitors in GBM spheroid cultures. Using results from two GBM patient-derived xenografts, we determined common changes to peptides derived from Phospholipase C, Gamma 1 (PLCG1) and Raf-1. Using PLC and Raf inhibitors, we found a significantly stronger growth inhibitory effect of the PLC inhibitor U73122 under restricted glucose conditions. In contrast, Raf inhibitors were significantly growth inhibitory regardless of the nutrient level tested. Together, our data demonstrate that kinase activity is altered in low glucose conditions and that kinomic profiling can assist with the identification of effective strategies to target GBM growth. Our data further suggest the importance of accurately modeling the tumor microenvironment to reproduce cancer cell signaling and develop drug screens for anti-cancer agents.